Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation for alleged violations of federal securities laws, urging affected investors to contact them before the August 12, 2025 deadline for lead plaintiff applications in a federal class action lawsuit [2][4]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, with sales revenue of $111 million, a year-over-year decline of 3.4%, and a full-year 2024 sales total of $440.1 million, down 10% from the previous year [5]. - In Q1 2025, the company reported revenue of $94.5 million, an 8% year-over-year decline, and a net loss of $37 million, or $0.28 per share, which is more than double the $16 million loss reported in Q1 2024 [6]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [5]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [7]. Allegations of Misconduct - The complaint against 3D Systems alleges that the company and its executives made false or misleading statements regarding the impact of weakened customer spending and overstated the company's resilience in challenging market conditions [4]. - It is also claimed that updated milestone criteria in the United Partnership would negatively affect the revenue from the Regenerative Medicine Program, leading to materially false public statements [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PR ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of misleading statements regarding the effectiveness and safety of its drug PGN-EDO51, which has led to significant stock price declines and a federal securities class action [2][4]. Group 1: Allegations and Legal Actions - The complaint against PepGen alleges violations of federal securities laws, including false statements about the effectiveness and safety of PGN-EDO51 and deficiencies in the CONNECT2 study [4]. - Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against PepGen is August 11, 2025 [2]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a 32.69% drop in stock price [5][6]. - Following a clinical hold notice from the FDA on December 16, 2024, due to safety concerns, PepGen's stock fell by 3.63% [7][8]. - A subsequent update on January 29, 2025, regarding safety concerns in the CONNECT1 study led to a further 21.74% decline in stock price [9][10]. - On March 4, 2025, PepGen announced a voluntary pause of the CONNECT2 study, resulting in an 18.86% drop in stock price [10]. - On May 28, 2025, PepGen disclosed that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].

Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified Holdings for irregularities in financial reporting related to its acquisition of Lugano Holdings, leading to a significant drop in stock price [1][3]. Group 1: Company Overview - Compass Diversified Holdings is a private equity firm headquartered in Westport, Connecticut [2]. - In 2021, Compass acquired a majority interest in Lugano Holdings, Inc., a high-end jewelry designer, for an enterprise value of $256 million [2]. Group 2: Legal Developments - The class action lawsuit pertains to investors who purchased Compass securities between May 1, 2024, and May 7, 2025 [1]. - Investors have until July 8, 2025, to seek appointment as lead plaintiff in the class action [2]. - On May 7, 2025, Compass disclosed irregularities in Lugano's financing, accounting, and inventory practices, necessitating a restatement of previously issued financial statements for 2024 [3]. Group 3: Market Impact - Following the announcement of the financial irregularities, Compass' stock price fell by $10.70 per share, a decline of over 62%, closing at $6.55 on May 8, 2025 [3].

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Napco Security Technologies, Inc. (NASDAQ: NSSC) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Napco Security caused the company to misrepresent Napco’s overall expected growth and strength in the Company’s hardware division, including, among other things, confidence in Napco’s ability to achieve i ...

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of NET Power Inc. related to misleading statements about Project Permian [1][2] Group 1: Allegations of Misrepresentation - Insiders at NET Power allegedly caused the company to misrepresent the likelihood of completing Project Permian on schedule, indicating it would be significantly more expensive due to supply chain issues and site-specific challenges [2] - Projections regarding the time and capital needed to complete Project Permian were deemed unrealistic, suggesting a significant negative impact on the company's business and financial results [2] - Public statements made by NET Power were materially false and misleading at all relevant times, according to the federal securities lawsuit [2] Group 2: Shareholder Actions - Shareholders who purchased NPWR shares prior to June 9, 2023, are encouraged to contact Kuehn Law for potential legal action, as there may be limited time to enforce their rights [3] - Kuehn Law offers to cover all case costs and does not charge investor clients, emphasizing the importance of shareholder participation in maintaining market integrity [4]

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including its gene therapy product, ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, inadequate trial protocols to detect severe side effects, and the potential for halting recruitment and dosing due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the deaths related to ELEVIDYS, causing an additional stock decline of over 8% [7]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [8].

Core Points - Holzer & Holzer, LLC is investigating Quantum Corporation for potential compliance issues with federal securities laws following the company's inability to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 [1] - Quantum disclosed that it is reviewing its accounting related to certain revenue contracts and the application of standalone selling price under applicable accounting standards, which led to a drop in its stock price [1] Company Information - Quantum Corporation trades on NASDAQ under the ticker QMCO [1] - The company has faced scrutiny due to its accounting practices, which may impact investor confidence and stock performance [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in cases of corporate misconduct [3] - The firm has a history of recovering significant amounts for shareholders affected by fraud, indicating a proactive approach to investor rights [3]

Core Viewpoint - Burford Capital Limited has provided an update regarding the removal of proposed tax provisions related to litigation finance from the US Senate's budget reconciliation bill, which has now been adopted without these provisions [1][2]. Company Overview - Burford Capital is a leading global finance and asset management firm focused on law, offering services in litigation finance, risk management, asset recovery, and various legal finance and advisory activities [3]. - The company is publicly traded on both the New York Stock Exchange (NYSE: BUR) and the London Stock Exchange (LSE: BUR), and operates through a global network of offices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Reddit, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the lawsuit is from October 29, 2024, to May 20, 2025, and the lead plaintiff deadline is August 18, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its success in this area [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding user engagement and advertising revenues due to changes in Google Search's algorithm [4]. - It is claimed that these algorithm changes led to a significant reduction in traffic to Reddit, which the defendants were aware of but failed to disclose [4]. - The lawsuit asserts that the true impact of these changes was not communicated to investors, resulting in damages when the information became public [4].